Matches in DBpedia 2015-10 for { ?s ?p "Cariprazine (trade name Vraylar, previously known as RGH-188) is an antipsychotic drug developed by Gedeon Richter. It acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. Positive Phase III study results were published for schizophrenia and mania early 2012, while Phase II studies in bipolar disorder I, and for bipolar depression are in progress. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder Rights are currently owned by Gedeon Richter and Actavis. The drug received FDA approval on September 17, 2015."@en }
Showing triples 1 to 1 of
1
with 100 triples per page.
- Cariprazine abstract "Cariprazine (trade name Vraylar, previously known as RGH-188) is an antipsychotic drug developed by Gedeon Richter. It acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. Positive Phase III study results were published for schizophrenia and mania early 2012, while Phase II studies in bipolar disorder I, and for bipolar depression are in progress. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder Rights are currently owned by Gedeon Richter and Actavis. The drug received FDA approval on September 17, 2015.".